COPD is a serious progressive long‐term lung disease estimated to affect 9–10% of adults over 40 years of age.1 The latest figures from the World Health Organization2 show that 65 million people across the globe are living with moderate to severe COPD.
Over the next decade, the number of deaths associated with COPD is predicted to increase by more than 30% to become the third leading cause of death worldwide by 2030.2
For over 25 years ResMed has been working to improve the lives of people with COPD and other breathing disorders. We're continually innovating to produce more advanced solutions for people with these conditions.
The HOT-HMV trial shows that home mechanical ventilation (HMV) combined with home oxygen therapy (HOT) significantly reduces the risk of hospital readmission or death in severe COPD patients after an acute COPD exacerbation requiring NIV.
The aim of treating stable COPD is to immediately relieve and reduce the impact of symptoms as well as reduce the risk of future exacerbations.
There are many positive outcomes for COPD patients being treated with NIV.